ArticleDiabetology & metabolic syndrome2026
Estimated glucose disposal rate outperforms conventional insulin resistance indices in predicting acute kidney injury risk among individuals with diabetes and prediabetes.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research advances on acute kidney injury and brain dysfunction.Frontiers in nephrology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) is a major global health concern, particularly in individuals with diabetes or prediabetes. While insulin resistance (IR) is implicated in AKI pathogenesis, the relationship between comprehensive IR measures-particularly the estimated glucose disposal rate (eGDR)-and AKI risk remains unclear.
methodsThis prospective cohort study analyzed 60,149 UK Biobank participants with diabetes or prediabetes. eGDR was calculated using waist circumference, hypertension status, and HbA1c. The primary outcome was incident AKI. Multivariable Cox models assessed the eGDR-AKI risk relationship. Predictive performance was compared against conventional IR indices using C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
resultsOver a median follow-up duration of 13.4 years, 6,259 participants developed AKI. Higher eGDR showed a strong inverse association with AKI risk (per SD increment, adjusted HR: 0.64; 95%CI: 0.61-0.66), with a 62% lower risk in the highest vs. lowest quartile (adjusted HR: 0.38, 95%CI: 0.34-0.43). The eGDR showed superior discriminative ability (C-index 0.709, 95%CI: 0.702-0.715) compared to other IR indices - including the triglyceride-glucose index (TyG, 0.665, 0.658-0.672), TyG-waist circumference (0.693, 0.686-0.700), triglyceride-to-HDL cholesterol ratio (0.661, 0.654-0.668), C-reactive protein-triglyceride-glucose index (0.679, 0.672-0.686), single-point insulin sensitivity estimator index (SPISE, 0.680, 0.673-0.687), metabolic score for insulin resistance (METS-IR, 0.694, 0.687-0.700), and lipid accumulation product (LAP, 0.669, 0.662-0.676) - while also demonstrating clinically meaningful improvements in risk reclassification (NRI 0.063-0.196; IDI 0.003-0.018).
conclusionLower eGDR, indicating severe IR, independently predicts higher AKI risk in dysglycemic individuals. As a composite measure integrating metabolic and vascular components, eGDR outperforms conventional IR indices in AKI risk stratification, suggesting its clinical utility for identifying high-risk patients who may benefit from targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.